Suppr超能文献

桥本甲状腺毒症患儿的结局。

Outcomes of children with hashitoxicosis.

机构信息

Department of Pediatrics, University of Messina, Messina, Italy.

出版信息

Horm Res Paediatr. 2012;77(1):36-40. doi: 10.1159/000334640. Epub 2012 Jan 26.

Abstract

AIM

To investigate hashitoxicosis outcome in 14 children with persistent absence of thyrotropin receptor autoantibodies who were followed for 1.3-8.8 years (mean 3.5 ± 2.5). Due to a more severe presentation, 4 patients required methimazole (subgroup A1), whilst in the remaining 10 cas es (subgroup A2) no treatment was given.

RESULTS

A definitive resolution of hyperthyroidism was recorded 8.3 ± 6.3 months after diagnosis, even though there was a wide variability between subjects (3-23 months). In subgroup A2, hyperthyroidism resolution occurred spontaneously and earlier with respect to subgroup A1 (4.8 ± 2.0 months after diagnosis vs. 17.0 ± 4.5, p = 0.00001). After hyperthyroidism resolution, no relapses were recorded in any patients. Hyperthyroidism duration positively correlated with thyroid peroxidase autoantibody (TPOAb) levels at presentation (r = 0.729, p = 0.002).

CONCLUSIONS

In all the 14 hashitoxicosis children with persistently absent thyrotropin receptor autoantibodies, the hyperthyroid phase was widely variable and always followed by definitive resolution with no relapses and persistent euthyroidism or hypothyroidism. In the few patients with a more severe presentation, methimazole treatment was required, and definitive hyperthyroidism resolution was delayed. In this subgroup, TPOAb levels at diagnosis were higher than in the subgroup with less severe presentation and earlier hyperthyroidism resolution, suggesting a relationship between TPOAb levels and severity of the disease.

摘要

目的

研究 14 例持续性甲状腺刺激素受体自身抗体阴性的桥本甲状腺毒症患儿的结局,这些患儿随访时间为 1.3-8.8 年(平均 3.5±2.5 年)。由于表现更严重,4 例患儿需要甲巯咪唑(A1 亚组),而其余 10 例患儿(A2 亚组)未进行治疗。

结果

在诊断后 8.3±6.3 个月,所有患儿的甲状腺功能亢进症均得到明确缓解,尽管患儿之间存在较大差异(3-23 个月)。在 A2 亚组中,甲状腺功能亢进症的缓解时间较 A1 亚组更早(诊断后 4.8±2.0 个月与 17.0±4.5 个月,p=0.00001)。甲状腺功能亢进症缓解后,所有患儿均未复发。甲状腺功能亢进症的持续时间与发病时甲状腺过氧化物酶自身抗体(TPOAb)水平呈正相关(r=0.729,p=0.002)。

结论

在所有 14 例持续性甲状腺刺激素受体自身抗体阴性的桥本甲状腺毒症患儿中,甲状腺功能亢进症期变化较大,均明确缓解,无复发,持续处于甲状腺功能正常或甲状腺功能减退状态。在表现更严重的少数患儿中,需要甲巯咪唑治疗,且明确的甲状腺功能亢进症缓解时间延迟。在该亚组中,诊断时的 TPOAb 水平高于缓解时间更早、表现较轻的亚组,提示 TPOAb 水平与疾病严重程度之间存在关系。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验